CN103301373B - Pharmaceutical composition for treating postpartum perineal mucosal lesions - Google Patents

Pharmaceutical composition for treating postpartum perineal mucosal lesions Download PDF

Info

Publication number
CN103301373B
CN103301373B CN201310269334.4A CN201310269334A CN103301373B CN 103301373 B CN103301373 B CN 103301373B CN 201310269334 A CN201310269334 A CN 201310269334A CN 103301373 B CN103301373 B CN 103301373B
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
brown
parched
mucosal lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310269334.4A
Other languages
Chinese (zh)
Other versions
CN103301373A (en
Inventor
朱月英
毕玉珍
姜春杰
吴君
冯涛
Original Assignee
朱月英
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 朱月英 filed Critical 朱月英
Priority to CN201310269334.4A priority Critical patent/CN103301373B/en
Publication of CN103301373A publication Critical patent/CN103301373A/en
Application granted granted Critical
Publication of CN103301373B publication Critical patent/CN103301373B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a pharmaceutical composition for treating postpartum perineal mucosal lesions, so as to solve the problem of treatment of postpartum perineal mucosal lesions. The pharmaceutical composition is characterized by being prepared from the following crude drugs: bark of himalayan coralbean, smallflower bracketplant herb, bobbin, alpinia japonica, parasitic loranthus, radix ranunculi ternate, dark malt, burnt medicated leaven, Chinese ephedra root, spina gleditsiae, peach gum, and rhizome anemones altaicae. The clinical test shows that the pharmaceutical composition has the characteristics of good curative effect and high safety on treatment of the postpartum perineal mucosal lesions, and is worthy of clinical application and popularization.

Description

A kind of pharmaceutical composition for the treatment of postpartum perineum mucosa infection
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of postpartum perineum mucosa infection.
Background technology
Puerperal uterus, cervix uteri, vagina, perineum can produce a series of change because hormonal readiness declines rapidly.For perineum, during childbirth, due to fetus extruding vagina collar extension.Usually cause perineum hyperemia, edema, or have laceration in various degree, fade away in after this 7 days.Meanwhile, perineal position is also because of pleat minimizing around, and intravaginal mucosa is smooth, and mucosal defense power reduces the symptoms such as easy secondary pruritus vulvae, vaginal dryness.In general, at short notice, vaginal mucosa is not easy to return to pregravidic situation completely, and only after stopping is breast-feeded, menstrual onset, ovarian function is normal, and under functions of hormones, vaginal mucosa just recovers normal gradually.
Current is for symptom for postpartum perineum mucosa infection mostly, and as given 50% magnesium sulfate dressing to alleviate edema, 1:5000 potassium permanganate liquid rinses the soak of cooperation 0.2% metronidazole solution to protect from infection.But in fact, because the basic pathology of morbidity is: puerperal, estrogen level declined rapidly, caused the relative atrophy of vaginal wall, mucosa is thinning, and in epithelial cell, glycogen content reduces, and intravaginal Ph value rises, local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.And magnesium sulfate, potassium permanganate liquid flushing liquor are also a kind of stimulations for mucosa, early stage myxedema problem can be solved, but unfavorable on the contrary to long-term prognosis.
Chinese medicine perineum Wet-dressing agent is many, but be mostly for Women of Childbearing Age, many containing the medicine except noxious dampness such as Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae in prescription, and the cause of postpartum perineum mucosa infection mainly mucosa is thinning causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more, causes aggravation.And said medicine bitter cold is unfavorable for postpartum recovery.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the little treatment postpartum perineum mucosa infection of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of postpartum perineum mucosa infection, it is characterized in that being prepared from by the crude drug of following weight proportion: Cortex erythrinae 10 ~ 30 parts, Herba Chlorophyti Laxi 6 ~ 12 parts, go back 3 ~ 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 ~ 12 parts, Herba Taxilli 3 ~ 10 parts, Radix Ranunculi Ternati 6 ~ 12 parts, Fructus Hordei Germinatus (parched to brown) 6 ~ 12 parts, Massa Medicata Fermentata (parched to brown) 6 ~ 12 parts, Radix Ephedrae 6 ~ 12 parts, Spina Gleditsiae 1 ~ 5 part, gumshiraz 3 ~ 10 parts, Rhizoma Anemones Altaicae 10 ~ 25 parts.
Chinese medicine of the present invention is prepared from by the raw material of following optimum weight part proportioning: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, flat.Return liver, kidney channel.Merit can wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Chlorophyti Laxi is herb or the root of feverfew Prenanthes henryi Dunn Prenanthes henryi Dunn.Bitter in the mouth; Cold in nature.Merit can heat-clearing and toxic substances removing; Dissipating blood stasis stops blooding.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.Merit can tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; Wind syndrome of head is had a headache; Weak breath consumption of essence; Early whitening of beard and hair.
Alpinia japonica (Thunb.) Miq., is Zingiberaceae Alpinia plants Alpinia japonica (Thunb.) Miq. Alpinia japonica Miq., is used as medicine with root stock.Nature and flavor are pungent, warm.Return lung, spleen, Liver Channel.Merit can dispelling wind and removing obstruction in the collateral, regulating QI to relieve pain.
Herba Taxilli, for Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser.Nature and flavor bitter, sweet, flat.Return liver, kidney channel.Merit can invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Ranunculi Ternati is the dried root of ranunculaceae plant Seynuns Kugelann Ranunculus ternatus Thunb..Nature and flavor sweet, acrid, warm.Return liver, lung meridian.Merit can eliminating stagnation, detumescence.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven of fermentation, fry to burnt brown according to frying method.Nature and flavor sweet, acrid, warm.Enter spleen, stomach warp.Merit can invigorating the spleen and regulating the stomach, helps digestion in adjusting.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, flat.GUIXIN, lung meridian.Merit can hidroschesis.
Spina Gleditsiae is the dry Spina jujubae of leguminous plant Fructus Gleditsia Gleditsia sinensis Lam..Nature and flavor are pungent, temperature.Return liver, stomach warp.Merit can be subsided a swelling poison holding, evacuation of pus, parasite killing.
Gumshiraz is rosaceous plant Fructus Persicae Prunus persica (L.) Batsch, the resin that trunk flows out.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Rhizoma Anemones Altaicae, is Ranunculaceae thimbleweed anemone altaica Anemone altaica Mey., is used as medicine with root stock.Nature and flavor are pungent, temperature.Merit can causing resuscitation with aromatic drugs, reduces phlegm, calms the nerves.
Composition principle: postpartum perineum mucosa infection often reduces because of ovarioestrogen level, and vaginal wall mucosa is thinning, in epithelial cell, glycogen content reduces, and intravaginal Ph value rises, and local resistance reduces, and pathogenic bacterium are easily invaded breeding and cause and inflammation.Cardinal symptom is that vaginal secretions increases and pruritus vulvae, burning sensation.The colpitic suppository of current Chinese traditional treatment, Wet-dressing agent are many, but be mostly for Women of Childbearing Age, many containing the medicine except noxious dampness such as Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae in prescription, and the cause of postpartum perineum mucosa infection mainly mucosa is thinning causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more, causes aggravation.The object of the invention is to avoid using dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, vaginal wall atrophy, mucosa this pathological change angle thinning is started with, and reaches the object of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in side, go back bobbin for monarch, the Cortex erythrinae dosage recorded in " China's book on Chinese herbal medicine " is: " for oral administration: to decoct soup, 6-12g "; Inventor to test in proof heavy dose of Cortex erythrinae (10 ~ 30g) and can recover by specific promotion vaginal wall mucosa, and goes back bobbin and have similar plants estrogen action, but this act as two-ways regulation, can not produce the low differentiation of estrogen excessive stimulation reproductive system cell;
2, characteristic of the present invention is also balance and restriction: records Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbid ", but puerperal resembling often with deficiency of YIN-blood, and now use Cortex erythrinae, then have and fear its hematozemia and cause yin asthenia generating intrinsic heat to occur; Therefore add Herba Chlorophyti Laxi and go back bobbin, also bobbin merit can train base by tonify deficiency, and can prevent Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and Herba Chlorophyti Laxi bitter in the mouth is cold in nature, utilize on the one hand it coldly to prevent heated, its merit can dissipating blood stasis hemostasis on the other hand, has out entire merit in blood system, prevent Cortex erythrinae to wander away dynamic blood, also can not affect Cortex erythrinae works orderly effect simultaneously; 2. in we, the use of Rhizoma Anemones Altaicae is: a causing resuscitation with aromatic drugs and benefaction, two Yin Yang balancings, and to balance the bitter cold of our invasion by pathogenic cold medicine of a cold nature thing, inventor's clinical research finds that Rhizoma Anemones Altaicae is activated yang and do not consume the moon in addition, is suitable for using puerperal; In prescription of the present invention, the application characteristic of Rhizoma Anemones Altaicae is: measure larger (consumption in " Chinese Pharmacopoeia " is 1.5-6g), so too disperse for preventing, gets again Radix Ephedrae convergence assistant system;
3, supplementary drug thing is fewer but better: get Alpinia japonica (Thunb.) Miq. assistant in side and help Herba Chlorophyti Laxi, it act as giving treatment in accordance with the tendency of pathological change, and heat conduction is descending; Radix Ranunculi Ternati and Herba Chlorophyti Laxi are arranged in pairs or groups the effect of removing toxic substances, eliminating stagnation, pain relieving; Herba Taxilli assistant helps goes back bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and contributes to drag residence in mucomembranous surface, penetration enhancement;
4, inventor's clinical research finds, Fructus Hordei Germinatus (parched to brown), the external of Massa Medicata Fermentata (parched to brown) decoct can promote local mucous membrane blood circulation;
5, Spina Gleditsiae is supplementary drug thing, and the consumption recorded in " China's book on Chinese herbal medicine " is: " for oral administration: to decoct soup, 6 ~ 12g ", and the present inventor's experimental study finds, gets low dose of Spina Gleditsiae decocting liquid and can improve in vitro vaginal mucosa cytoactive;
6, the homogeneous medicine multiple-effect of institute's thing of getting it filled in side, contributes to reducing medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, and each raw material dosage is for all to have good curative effect in following weight parts scope.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Cortex erythrinae 20g, Herba Chlorophyti Laxi 10g, go back bobbin 6g, Alpinia japonica (Thunb.) Miq. 10g, Herba Taxilli 6g, Radix Ranunculi Ternati 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Spina Gleditsiae 2g, gumshiraz 6g, Rhizoma Anemones Altaicae 20g.
The preparation method of embodiment 1 is: by Cortex erythrinae, Herba Chlorophyti Laxi, go back bobbin, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Radix Ranunculi Ternati, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Spina Gleditsiae, gumshiraz, the decoction of Rhizoma Anemones Altaicae mixing and water adding, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges soak, once a day.
Embodiment 2, crude drug weight proportion: Cortex erythrinae 10 parts, Herba Chlorophyti Laxi 6 parts, go back 3 parts, bobbin, Alpinia japonica (Thunb.) Miq. 6 parts, Herba Taxilli 3 parts, Radix Ranunculi Ternati 6 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Massa Medicata Fermentata (parched to brown) 6 parts, Radix Ephedrae 6 parts, Spina Gleditsiae 1 part, gumshiraz 3 parts, Rhizoma Anemones Altaicae 10 parts.
Embodiment 3, crude drug weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts.
Embodiment 4, crude drug weight proportion: Cortex erythrinae 30 parts, Herba Chlorophyti Laxi 12 parts, go back 10 parts, bobbin, Alpinia japonica (Thunb.) Miq. 12 parts, Herba Taxilli 10 parts, Radix Ranunculi Ternati 12 parts, Fructus Hordei Germinatus (parched to brown) 12 parts, Massa Medicata Fermentata (parched to brown) 12 parts, Radix Ephedrae 12 parts, Spina Gleditsiae 5 parts, gumshiraz 10 parts, Rhizoma Anemones Altaicae 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) by Cortex erythrinae, Radix Ranunculi Ternati, Radix Ephedrae coarse powder distilling under reduced pressure extraction volatile oil respectively, and mixing for standby use after collecting, medicinal residues mixing for standby use;
(2) will go back bobbin decompression decoction 2 times, each 30min, collecting decoction, filters after leaving standstill, obtains filtrate for subsequent use;
(3) gained medicinal residues in Herba Chlorophyti Laxi, Alpinia japonica (Thunb.) Miq., Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Spina Gleditsiae, gumshiraz, Rhizoma Anemones Altaicae and step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, filter after leaving standstill, obtain filtrate for subsequent use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to obtain dry extract;
(5) spray in step 4 gained dry extract by gained volatile oil in step 1, mixing, cross 100 mesh sieves, subpackage forms.
The efficient combination of said medicine, coordinates mutually, effectively reach the object for the treatment of postpartum perineum mucosa infection, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case selection: in January, 2011 ~ 2013 are diagnosed as postpartum perineum mucosa infection 148 example year June, are full-term normal delivery primipara.Get rid of trichomonal vaginitis, monilial vaginitis, urine is cultivated negative.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all cases is all clarified a diagnosis according to medical history, gynecologial examination.Symptom is perineum pruritus, xerosis vulae, the pale or flushing of vaginal mucosa or have little petechia, and vaginal health scoring <15 divides.
1.1.3 divide into groups: be divided into matched group 48 example, soak group 50 example and powder group 50 example.Compare in age, the state of an illness, the course of disease before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.2 method.
1.2.1 Therapeutic Method: matched group adopts 1:5000 potassium permanganate liquid to rinse the soak of cooperation 0.2% metronidazole solution, 1 time/d.Soak group with gained decoct soak in the embodiment of the present invention 1,1 time/d.Powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the present invention 3,1 time/d.It within 7 days, is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after medication, and according to vaginal health point system (VHS) scoring, determine that symptom improves situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Effective: clinical symptoms, sign turn for the better by and large; Effective: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.4 statistical analysis: SPSS 16.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data t checks, enumeration data χ 2inspection.
2 results.
2.1 vaginal symptoms improve situations: after medication 3d, matched group 27.08%(13/48) patient, and soak group and all case pruritus of vagina of powder group, drying, pain symptom all start the improvement that obtains in various degree.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and pale, the flushing in surface and bleeding are clearly better.According to vaginal health standards of grading, vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, secretions 5 project score values.Before soak group patient medication, scoring is 9.29 ± 2.36, and average of marking after medication 7d is 14.27 ± 2.82.Before powder group patient medication, scoring is 10.62 ± 2.72, and average of marking after medication 7d is 17.27 ± 2.28.Compare before and after medication, after two groups of patient treatments, vaginal health scoring is all obviously increased (P<0.05).
2.2 3 groups of Comprehensive Clinical comparitive study: after medication 7d, matched group cure rate, obvious effective rate, effective percentage, inefficiency are respectively 31.25%, 43.75%, 18.75%, 6.25%; The cure rate of soak group, obvious effective rate, effective percentage, inefficiency are respectively 56.00%, 34.00%, 10.00%, 0.00%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 70.00%, 18.00%, 12.00%, 0.00%.Three groups are compared, and the cure rate of soak group and powder group, total effective rate are apparently higher than matched group (P<0.05), and the cure rate of powder group is apparently higher than soak group (P<0.05).
2.3 adverse reaction rates: three groups of patients all do not occur obvious adverse reaction.
3. conclusion.
This result of study shows, and soak group of the present invention and powder group treatment postpartum perineum mucosa infection total effective rate are 100%, and the cure rate of powder group is higher than soak group.Have the advantage that untoward reaction is comparatively light, safety is higher.

Claims (1)

1. treat a pharmaceutical composition for postpartum perineum mucosa infection, it is characterized in that being prepared from by the crude drug of following weight proportion: Cortex erythrinae 20 parts, Herba Chlorophyti Laxi 10 parts, go back 6 parts, bobbin, Alpinia japonica (Thunb.) Miq. 10 parts, Herba Taxilli 6 parts, Radix Ranunculi Ternati 10 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Massa Medicata Fermentata (parched to brown) 10 parts, Radix Ephedrae 10 parts, Spina Gleditsiae 2 parts, gumshiraz 6 parts, Rhizoma Anemones Altaicae 20 parts; The occupation mode of described pharmaceutical composition is that powder pudendum and intravaginal are blown deposited.
CN201310269334.4A 2013-07-01 2013-07-01 Pharmaceutical composition for treating postpartum perineal mucosal lesions Expired - Fee Related CN103301373B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310269334.4A CN103301373B (en) 2013-07-01 2013-07-01 Pharmaceutical composition for treating postpartum perineal mucosal lesions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310269334.4A CN103301373B (en) 2013-07-01 2013-07-01 Pharmaceutical composition for treating postpartum perineal mucosal lesions

Publications (2)

Publication Number Publication Date
CN103301373A CN103301373A (en) 2013-09-18
CN103301373B true CN103301373B (en) 2015-04-08

Family

ID=49127379

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310269334.4A Expired - Fee Related CN103301373B (en) 2013-07-01 2013-07-01 Pharmaceutical composition for treating postpartum perineal mucosal lesions

Country Status (1)

Country Link
CN (1) CN103301373B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316270B (en) * 2013-07-01 2015-03-18 丁霄雁 Preparation method of powder of medicine for treating postnatal perineum mucosal lesion
CN103721083B (en) * 2014-01-13 2015-11-18 姜霞 A kind of pharmaceutical composition for gestational vulvareczema

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148205C (en) * 2001-01-10 2004-05-05 刘从清 Yinkang lotion
CN100409859C (en) * 2006-05-15 2008-08-13 贵州柏强制药有限公司 'Fu Yan Jing' film for treating gynecological inflammation and preparation method thereof
CN101406558A (en) * 2007-12-18 2009-04-15 展翼 Gynaecologic washing lotion for preventing and treating colpitis
CN102018754B (en) * 2009-09-11 2013-04-24 李强 Vaginal effervescent tablet and making process thereof

Also Published As

Publication number Publication date
CN103301373A (en) 2013-09-18

Similar Documents

Publication Publication Date Title
CN103520572B (en) A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof
CN102836409B (en) Traditional Chinese medicine for treating postpartum lochiorrhea and preparation method
CN104958607A (en) Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof
CN103301353B (en) Pharmaceutical composition for treating atrophic vaginitis
CN103285284B (en) Medical composition for treating senile vaginitis
CN103341092B (en) Preparation method of powder for treating atrophic vaginitis
CN103356932B (en) A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia
CN103301373B (en) Pharmaceutical composition for treating postpartum perineal mucosal lesions
CN104940718A (en) Pharmaceutical composition for treatment of chronic cholecystitis and preparation method thereof
CN103330867B (en) Preparation method of powder for treating senile vaginitis
CN103316270B (en) Preparation method of powder of medicine for treating postnatal perineum mucosal lesion
CN103285300B (en) Medicinal composition for treating stress incontinence
CN104887950A (en) Mastitis treatment traditional Chinese medicine compound
CN103301374B (en) Pharmaceutical composition for treating postpartum non-specificity vaginitis
CN103330896B (en) Preparation method of powder for treating postpartum nonspecific vaginitis
CN103341094B (en) Preparation method of powder for treating vulva squamous epithelial cell hyperplasia
CN101366878A (en) Traditional Chinese medicine for female acyesis and aphoria and preparation method thereof
CN103191399A (en) Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period
CN103041194B (en) Traditional Chinese medicine composition for curing chronic eczema and preparation method thereof
CN105169111A (en) Traditional Chinese medicine composition for treating chronic urticaria and application of traditional Chinese medicine composition
CN105232997A (en) Chinese herba preparation used for treating endometritis and preparing method
CN105267895A (en) Medicine for treating bovine postpartum blood stasis type placenta retension and preparing method thereof
CN104857414A (en) Medicine composite for treating chronic simple rhinitis
CN103316258B (en) Medicine composition for treating infantile vaginitis
CN103301354B (en) Preparation method of powder for treating infantile vaginitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Zhu Yueying

Inventor after: Bi Yuzhen

Inventor after: Jiang Chunjie

Inventor after: Wu Jun

Inventor after: Feng Tao

Inventor before: Ding Xiaoyan

Inventor before: Feng Tao

Inventor before: Geng Hui

TA01 Transfer of patent application right

Effective date of registration: 20150306

Address after: 255036, Shandong, Ji'nan Province, Zhangqiu City, Zhangqiu City, Shandong province senior officials Zhai Zhai Township Health Center

Applicant after: Zhu Yueying

Address before: 255036 Zibo Central Hospital, Shandong, Shandong, China, Zhangdian, No. 54, No.

Applicant before: Ding Xiaoyan

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 255036 ZIBO, SHANDONG PROVINCE TO: 255036 JINAN, SHANDONG PROVINCE

Free format text: CORRECT: INVENTOR; FROM: DING XIAOYAN FENG TAO GENG HUI TO: ZHU YUEYING BI YUZHEN JIANG CHUNJIE WU JUN FENG TAO

ASS Succession or assignment of patent right

Owner name: ZHU YUEYING

Free format text: FORMER OWNER: DING XIAOYAN

Effective date: 20150306

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent for invention or patent application
C14 Grant of patent or utility model
GR01 Patent grant
EXPY Termination of patent right or utility model
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150408

Termination date: 20150701